In non-clinical studies, the GSK-3 inhibitor, LY2090314, inhibited cell viability and induced apoptosis in vitro in AML cell lines, MLL-translocated leukemia, erythroleukemia, CML, T-ALL (Eli Lilly and Company, Indianapolis, IN). Here, KMT2A is linked to acute myeloid leukemia.